Related Experiment Video
Updated: Jun 22, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection
Angelo Iacobellis1, Angelo Andriulli
1'Casa Sollievo Sofferenza' Hospital, Division of Gastroenterology, IRCCS, Viale Cappuccini 1, 71013 San Giovanni Rotondo, Italy.
Abstract:
Liver cirrhosis secondary to HCV infection is a chronic disorder that carries high morbidity and mortality. Approved antiviral treatment for this condition at present includes peginterferon in combination with ribavirin. Treatment is only recommended for a well-compensated liver cirrhosis, whereas antiviral therapy is commonly not implemented in cirrhotics with signs of liver decompensation, over the concern that the use of peginterferon and ribavirin might expose patients to severe treatment-related side effects. This review focuses on data available to support both efficacy and safety of antiviral therapy in both compensated and decompensated cirrhotic patients.
Related Concept Videos
Hepatitis
Retrovirus Life Cycles
Cirrhosis II: Pathophysiology
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Cirrhosis I: Introduction
